Artur Widak | Nurphoto | Getty Images
Moderna
announced on Wednesday that it is advancing its combination vaccine targeting Covid-19 and the flu to the final stage trial in adults aged 50 and above. This move comes after the positive results demonstrated in an early to mid-stage study.
The biotech company aims to secure regulatory approval for its mRNA-1083 shot by 2025.
Moderna, along with other vaccine manufacturers like
Pfizer
, believe that combination vaccines can simplify the process of safeguarding oneself against respiratory viruses that typically surge simultaneously during certain times of the year.
Stéphane Bancel, Moderna CEO, stated that combination vaccines offer an invaluable opportunity to enhance the consumer and provider experience, improve compliance with public health recommendations, and deliver value to healthcare systems. Moderna is excited to advance the development of combination respiratory vaccines into Phase 3 and looks forward to collaborating with public health officials to address the significant seasonal threat posed by these viruses.
In the early to mid-stage clinical trial, the mRNA-1083 shot elicited an immune response comparable to or greater than the immune responses generated by two currently available flu vaccines from
GlaxoSmithKline
.
Additionally, Moderna’s combination shot induced an immune response similar to its bivalent Covid-19 vaccine, which targets the omicron variants BA.4 and BA.5, as well as the original strain of the virus.
The trial evaluated the combination shot in two different age groups: individuals aged 50 to 64 and participants aged 65 to 79.
According to Moderna, the safety data of mRNA-1083 was similar to that of the standalone Covid-19 shot, with no new safety concerns identified for the combination vaccine.
Moderna is also developing a combination shot targeting the flu and RSV (Respiratory Syncytial Virus), as well as another vaccine encompassing all three respiratory viruses: Covid-19, flu, and RSV.
Meanwhile, Pfizer and
BioNTech
are also developing a vaccine that targets both Covid-19 and the flu. They have initiated a phase one trial for this vaccine in November and anticipate its launch to be in 2024 or later.
Denial of responsibility! Vigour Times is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
